News

November 27, 2017

Claritas Genomics has launched the new and improved high resolution deletion/duplication array for its Claritas Clinical Exome (CCE) and Region of Interest (ROI) tests. It can be ordered as a standalone array or as a companion to the CCE and ROIs. The new high resolution array contains 800K probes for CNVs and 100K SNPs. More information can be found here.

November 21, 2017

Claritas Genomics is pleased to announce the Severe Combined Immunodeficiency (SCID) Region of Interest assay, which was developed in collaboration with leading experts in pediatric immunology and evaluates 59 genes related to known causes of SCID. More information on the assay can be found here....

November 07, 2017

Claritas will be exhibiting at the 2017 Labroots Clinical Diagnostics & Research virtual event on November 8th and 9th. Visit the website to learn more about the event. Register here.

October 16, 2017

Claritas will be attending ASHG 2017 in Orlando, Florida this week! Stop by our booth (#761) to learn more about our newest offerings and check out our poster (#2507) on "Detecting Mitochondrial Heteroplasmy for Clinical Diagnostics" which will be presented at 2:00pm on Thursday by John Thompson, PhD and Chief Technology Officer, and Eric White, PhD and Director of Assay and Technology Development....

September 25, 2017

Claritas Genomics has launched the new and improved Bone Marrow Failure Region of Interest NGS test, complete with 8 additional genes and 19 deep intron variants. The Bone Marrow Failure Region of Interest test was initially released in August, 2016. For more details on the updated assay, please visit our Bone Marrow Failure Region of Interest test page....

June 22, 2017

Claritas Genomics is pleased to announce it has received approval from the New York State Department of Health for three Region of Interest tests and Mitochondrial DNA analysis for the Claritas Clinical Exome. For the full list of NYS approved offerings, please visit our For New York State Providers page. Read the full press release...

May 03, 2017

The HLH Region of Interest assay is designed to assess genes that may cause autosomal recessive or X-linked recessive forms of primary HLH. Developed in collaboration with experts in the Division of Immunology at Boston Children’s Hospital, this Region of Interest evaluates 20 genes related to the known causes of HLH within a rapid turnaround time. More information can be found here....

January 30, 2017

Claritas is pleased to announce the addition of the mitochondrial DNA analysis to their Flagship Claritas Clinical Exome. When ordered, the mitochondrial genome and exome are sequenced simultaneously by deep NGS sequencing. More information is available here....

January 05, 2017

On January 4, 2017, Claritas Genomics received the New York State Clinical Laboratory Permit with specific approval for the Claritas Clinical Exome and the Pediatric Neurology Region of Interest. Read the Press Release here. ...

January 05, 2017

Dr. Stephanie Hallam joined Claritas Genomics on November 29, 2016, as Vice President of Molecular Diagnostics. Read the full press release here....

About Claritas

Claritas Genomics serves children affected with complex genetic disorders by providing timely and accurate results, resolving families’ long search for answers. By combining clinical expertise of the world’s best pediatric specialists with innovative platform solutions, Claritas is working to improve patient care and enable new discoveries. We are committed to the highest quality and accessibility of information and our interpretive services and unique approach to reporting set the standard for reliably and clearly communicating genetic information.

Now is the time to integrate genomics into clinical practice to inform, guide and improve medical treatment for kids around the world.